Featured Publications
Associations of meningioma molecular subgroup and tumor recurrence
Youngblood MW, Miyagishima DF, Jin L, Gupte T, Li C, Duran D, Montejo JD, Zhao A, Sheth A, Tyrtova E, Özduman K, Iacoangeli F, Peyre M, Boetto J, Pease M, Avşar T, Huttner A, Bilguvar K, Kilic T, Pamir MN, Amankulor N, Kalamarides M, Erson-Omay EZ, Günel M, Moliterno J. Associations of meningioma molecular subgroup and tumor recurrence. Neuro-Oncology 2020, 23: 783-794. PMID: 33068421, PMCID: PMC8099468, DOI: 10.1093/neuonc/noaa226.Peer-Reviewed Original ResearchConceptsDivergent clinical coursesMolecular subgroupsClinical courseClinical outcomesProgression-free survivalExtent of resectionKaplan-Meier analysisLong-term outcomesLow-grade tumorsCox proportional hazardsDistinct clinical outcomesPostoperative radiationIndependent predictorsMale sexRecurrence rateSurveillance imagingTumor recurrencePrevious recurrencesClinical prognosticationKi-67Outcome dataAggressive subgroupRecurrenceElevated recurrenceProportional hazards
2020
Clinical and economic burden of neurofibromatosis type 2 in the United States
Koo AB, Yeung JT, Freedman IG, Lee JH, Ahmed OM, Ma AK, Miyagishima DF, DiLuna M, Kahle K. Clinical and economic burden of neurofibromatosis type 2 in the United States. Clinical Neurology And Neurosurgery 2020, 197: 106053. PMID: 32683193, DOI: 10.1016/j.clineuro.2020.106053.Peer-Reviewed Original ResearchConceptsOpen resectionPatient demographicsRisk factorsMeningioma resectionMulti-year cross-sectional studyNeurofibromatosis type 2 (NF2) patientsSpine tumor resectionCommon admission diagnosesNational Inpatient SampleType 2 patientsCross-sectional studySignificant independent associationNeurofibromatosis type 2Regression analysisInflation-adjusted costAdmission diagnosisHospital stayDischarge weightIndependent predictorsObstructive hydrocephalusSurgical interventionDiagnosis codesHospital characteristicsInpatient populationInpatient Sample